Recombinant Human DTNb Protein，His

DTNb, or Diphtheria Toxin-Nontoxic Binary Protein, is an engineered protein derived from the diphtheria toxin's structure with modifications that render it non-toxic while retaining its ability to bind to cells. This research has gained traction due to the potential applications of DTNb in targeted drug delivery and immunotherapy. The interest in DTNb stems from the need for more effective therapeutic strategies, particularly in cancer treatment, where conventional methods can result in significant side effects and systemic toxicity. By utilizing DTNb's ability to specifically target and enter cells, researchers aim to develop innovative treatments that can deliver therapeutic agents directly to diseased cells, thus minimizing damage to healthy tissues. Furthermore, studies have explored the fusion of DTNb with various effector domains, enhancing its therapeutic efficacy. This protein's modular nature allows it to be fine-tuned for specific applications, making it a promising candidate in the ever-evolving field of biomedicine. Overall, the research into DTNb not only highlights its potential utility in disease treatment but also underscores the importance of engineered proteins in advancing medical interventions.